key: cord-0771014-dx2mwm71
authors: Malhotra, Hardeep Singh; Gupta, Prashant; Mehrotra, Divya; Dandu, Himanshu; Kohli, Neera; Verma, Veerendra; Kaur, Apjit; Kumar, Neeraj; Prabhu, Vikas; Singh, Manish Kumar; Jaiswal, Riddhi; Mishra, Brijesh; Ojha, Bal Krishna; Bhardwaj, Nitin Dutt; Atam, Virendra; Puri, Bipin
title: COVID-19 associated mucormycosis: Staging and management recommendations (Report of a multi-disciplinary expert committee)
date: 2021-08-11
journal: J Oral Biol Craniofac Res
DOI: 10.1016/j.jobcr.2021.08.001
sha: 127b62366d08f13f3e2267606a3469ed89e97617
doc_id: 771014
cord_uid: dx2mwm71

Even before the onslaught of COVID-19 pandemic could settle, the unprecedented rise in cases with COVID-19 associated mucormycosis has pushed the medical health to the fringe. Hyperglycaemia and corticosteroids appear to be the most consistent associations leading to the commonest manifestation of mucormycosis, Rhino-Orbito-Cerebral Mucormycosis. To address challenges right from categorisation and staging of the disease to the management of relentless progression, a multi-disciplinary expert committee was formed to handle the task in an evidence-based format to enforce best practices. The report of the committee on one hand attempts to succinctly present the currently available evidence while at the other also attempts to bridge the evidence-deficient gaps with the specialty-specific virtuosity of experts.

The scope of the committee included all 'COVID-19 positives' or 'post-COVID-19 patients' suspected of or diagnosed with COVID-19 associated Mucormycosis, with special focus on COVID-19 associated Rhino-Orbito-Cerebral Mucormycosis (C-ROCM). C-ROCM included patients in the acute as well as in the post-COVID-19 state. Acute COVID-19 state was defined up to 4 weeks from the date of onset of first symptom; a state thereafter, as per Centers for Disease Control and Prevention, was defined as the post-COVID-19 state. 2 The objectives were to critically appraise the available literature and formulate evidence-based guidelines to help in prevention, early detection and management of C-ROCM based on severity of disease and rational use of medications. At the time of submission of this report more than 400 admissions of C-ROCM had taken place and recent experiences were amalgamated into the existent evidence. Approval of the Institutional Ethics Committee was obtained prior to data analysis. The committee conducted a total of 8 meetings and more than 10 mortality audits to arrive at suggestions and recommendations mentioned in the paper.

The estimated prevalence of mucormycosis is approximately 70-times higher in India when compared with the developed world. 3, 4 The current extrapolations done from data obtained from a series of publications estimate the prevalence to be around 14 cases per 100,000 population. 3 There are definite indications that the prevalence of mucormycosis is rising in India and that seems to be strongly associated with the rising trend related with diabetes mellitus. 5-7

The evidence on pathogenesis of mucormycosis was reviewed; it has been summarized as agent-based factors and host-based factors.

There are several genera and species in the order mucorales; Rhizopus, Mucor, Lichtheimia (formerly Absidia), Cunninghamella, Rhizomucor, Apophysomyces spp. and Saksenaea are the ones commonly associated with Mucormycosis. Species of genera Rhizopus, Mucor and Lichtheimia account for almost 3/4 th of all cases with mucormycosis. Rhizopus spp. have been isolated most frequently in these cases, especially in the central nervous system (CNS) forms of Mucormycosis; Lichtheimia spp. are the second most prevalent ones but depending on the geographical region either of Mucor spp. or Lichtheimia spp. may be seen as the dominant form. 4,8-10 2.1.1. The pathogenic mechanisms associated with the aggressive nature of Mucormycosis have been best studied in Rhizopus especially in diabetics. The important factors defined in this regard are CotH (spore coating) fungal protein, GRP78 (glucose-regulated protein, molecular chaperone belonging to the family of heat shock proteins) endothelial cell receptor upregulation and enzymes modulating the sequestration of iron. Other factors associated with germination of spores, cell wall and immune evasion have also been defined. 11,12 2.1.2. Iron, in the free form, helps in the proliferation of invading fungi and has been shown to be a predisposing factor for Mucormycosis. 13 Expression patterns studied in Lichtheimia in this regard, reveal the possible pathways involved in the utilisation of iron. These may be summarized as the reductive iron assimilation, a siderophore permease pathway and a heme oxygenase pathway. 14 2.1.3. Hyperglycemia and ketone reductase: Uncontrolled sugars (hyperglycemia) in known diabetics, newly diagnosed diabetics and in cases secondary to corticosteroid usage demonstrate reduce capability of the host in combating fungi. This can range from impaired ciliary motility of nasal mucosa to ineffective phagocytosis of the invading organism besides providing them an excellent substrate for proliferation. Presence of ketone reductase in the fungi help them thrive through critical situations when there is ketoacidosis and metabolic acidosis. 13 2.2. Host-related factors 2.2.1. Important host-related factors identified/proposed till date 15,16 are summarized in Table 1 .

Literature on associations obtained from previous Mucormycosis-related outbreaks was reviewed to look at interactions, beyond the host-related factors, that could have possibly led to a surge in the number of patients in the current pandemic. 17 The shortlisted relevant associations were:

 Dirty linen, contaminated linen shelves and dirty bins  Contaminated air handling units and ventilation ducts  Negative pressure isolation rooms  Water leak (wall dampness leading to accumulation of fungus)  Hospital construction; dust and moisture  Fungal contamination of nebulizer devices 18 The committee recommends that the known associations be taken care of preemptively. The committee came across two more significant associations but were found irrelevant in the current scenario. These were:

 Fungal contamination of medication (methylprednisolone)  Environmental disruptions (more relevant to cutaneous mucormycosis) 6. How to diagnose mucormycosis? 6.1. Specimen: The first step in diagnosing C-ROCM is to conduct a diagnostic nasal endoscopy (DNE) and obtain nasal tissue or nasal scrapings from the affected area. 25, 26 Tissue biopsies constitute the best specimen for the diagnosis of mucormycosis. (Figure 1 ) If a biopsy is not possible, nasal scrapping and high nasal swabs should be used for direct examination; though high nasal swab and discharges are unreliable as the yield is low in microscopy and cultures. 16 In case of sinusitis, sinus biopsies must be taken. It is prudent to collect the specimen before initiating antifungal therapy as the morphological features may be altered, reducing the ability to definitively differentiate mucorales species from other filamentous fungi in microscopy. 27 Multiple biopsies may be needed if on DNE the infection appears patchy. It is emphasized that a repeat biopsy may be required if the microscopy or culture is negative, but the patient continues to have signs of progression.

Specimen such as tissue (whole, uncrushed) must be collected in at least 1 ml of sterile saline in a sterile leak-proof container and must be immediately transported (within two hours) to the laboratory at room temperature as excessive cold and heat are detrimental to fungal viability. If the delay is inevitable, it is suggested that transport occurs in less than 24 hours after collection. When immediate processing is not possible, the specimen should be held at ambient temperatures. 28 6.3. Precautions to be taken with sample processing: Nasal tissue must not be crushed or minced in the laboratory before processing for culture as fungal hyphae are damaged by these procedures. 27 6.4. Microscopy: Direct microscopy of clinical specimens, allows a rapid presumptive diagnosis of mucormycosis in 10-20% KOH (Potassium hydroxide) in the laboratory. 28 Addition of Calcoflour white to KOH enables easy visibility even in the presence of digested human cells and other material. Mucorales hyphae are distinct refractile hyphae of 6-16 µm diameter, aseptate or partially septate, with right angle branching and ribbon-like folding. 25 (Figure 2A) The growth of the mucorales tends to be rapid, with mycelial elements expanding to cover the entire culture media plate or tube in only a few (1-7) days. (Figure 2B ) 6.5.1. Culture Identification: Culture identification is done either by conventional methods such as slide culture or lactophenol cotton blue preparations ( Figure  2C) 34 In most patients, the extra-sinus involvement occurs with intact bones indicative of perineural/perivascular invasion; here, MRI scores over CT. 35 In some patients, CT may show bone rarefaction, erosions, permeative destruction and septal perforation. 7.1.3. Because of a superior resolution, MRI provides a better visualization of the involved orbital soft tissue, infratemporal fossa, intracranial structures, perineural invasion and vascular compression or obstruction. MRI is also better than CT because iodinated contrast used in CT adds to kidney damage in these patients who are likely to be on nephrotoxic drugs such as amphotericin, etc. 34 T2-weighted images show an isointense to mildly hypointense, heterogenous, or hyperintense sinonasal soft tissue lesions. Hyperintense mucosal thickening and intra-sinus hyperintense fluid may be seen; presence of a fluid level should always take into consideration the possibility of a secondary bacterial infection. Variable signal intensity, due to iron and manganese contained in the fungal elements, may be seen. 36 Common sites of extra-sinus involvement are orbit and face, followed by orbital apex, masticator space, pterygopalatine fossa, skull base, cavernous sinus and brain parenchyma (with or without vascular involvement). These changes are more evident on T2 fat-suppressed images. 7.1.4. On GAD-contrast, patterns of enhancement may include either an intense homogenous, or heterogeneous, or complete central non-enhancement, with or without a thin irregular rim of peripheral enhancement. Enhancing nerves are a sign of perineural invasion. Extensive angioinvasion is considered as the main cause leading to vascular thrombosis and tissue necrosis. Gadolinium enhanced MRI is the radiological gold standard for the evaluation of orbital extension of disease. Enlargement of medial rectus muscle is an early sign, while fat stranding, loss of contrast enhancement, thickening and straightening of the optic nerve indicate significant involvement. 7.1.5. Restriction on DWI and corresponding hypointensity on ADC maps is noted in the involved areas, presumably a result of fungal angioinvasion, similar to that seen in other ischemic & necrotic lesions. 37 For appropriate evaluation of infarcts or infarct-like lesions, MR angiography is advisable. 7.1.6. Two important signs have been noted in such patients. First, the "black turbinate sign" evident as non-enhancing dark and mottled turbinates; 38 second, the "guitar pick sign" (suggestive of an advanced disease) occurring as a result of tenting of posterior surface of globe from retrobulbar inflammatory soft tissue. 39 (Figure 3 ) 7.1.7. Once in a while, MR spectroscopy may aid in the diagnosis if the lesions bear semblance to demyelinating lesions.

Cases with COVID-19 may be predisposed to thromboembolic phenomenon. It is, thus, advisable to get an echocardiography done in patients who are dyspnoeic (right-sided overload as a result of pulmonary complications) and those who are labelled having stroke or stroke-like lesions (cardioembolism).

There are no serum markers for the diagnosis of mucormycosis. However, in a few complicated cases or where the diagnosis is equivocal, galactomannan and 1,3 β D-glucan may be estimated to rule out concomitant or disguised Aspergillosis.

The committee did not find an established scheme in this regard. A proposal reviewed in light of extant global guidelines for the diagnosis and management of Mucormycosis appeared suitable for application as it followed the most commonly used methods for diagnostic categorisation. 16, 25 The diagnostic categories may, therefore, be summarised as follows: Table 3 ) since the denotations listed may get affected unrelated with the stage of disease.

The recommendations of the committee have been summarized in Table 4 . it has been shown that the survival doubles (61%) if the treatment is initiated within the first 12 days of symptoms. 1 The committee recommends an early treatment and advocates that it may be initiated in probable cases too, pending microbiological confirmation. (Figure 4 ) 11.1.2. The first-line drug of choice for the treatment of Mucormycosis is Liposomal-Amphotericin B (L-AmB). 25 L-AmB is the preferred AmB due to a lower incidence of nephrotoxicity, higher tissue penetrability and higher tissue concentration. 41, 42 Other available formulations of Amphotericin-B, Amphotericin B lipid complex (ABLC) and Amphotericin B deoxycholate (ABDC, conventional AMB), may also be used in situations with either shortage or unavailability of L-AmB. 41 Data on the use of amphotericin B colloidal dispersion is sparse; coupled with its poor availability or unavailability, its preference over the aforementioned forms of AmB cannot be recommended. 11.1.3. ABDC, on the other hand, has been used extensively, has better availability and is the cheapest of the lot. ABDC can be used in the absence of L-AmB but renal parameters and potassium levels need to be monitored. It can be used if there is <1.5-fold rise in creatinine from baseline or the decrease in estimated GFR is <25% within 7 days of initiation of ABDC. If the tolerance is good, use it for a minimum for 2 weeks, up to 4-6 weeks, before stepping down. As a L-AmB sparing therapy, patients can be initiated directly on ABDC; only when there is a ≥1.5-fold rise in creatinine from baseline or the decrease in estimated GFR is >25% within 7 days of its initiation, a shift must be made. 42 11.1.4. In the event that AmB preparations cannot be given as the first line of therapy due to contraindications or non-availability, either parenteral or oral forms of Isavuconazole are recommended as an alternative. This is an FDA approved agent for the treatment of Mucormycosis. Posaconazole has also been used for treatment though it is preferred as a prophylactic agent for mucormycosis in transplant patients. 43 11.1.5. Early step-down therapy to Isavuconazole or Posaconazole (before 4-6 weeks of any AmB) should be considered if any form of amphotericin is not tolerated, or if there is >2-fold rise in creatinine from baseline or if the decrease in estimated GFR is >50% suggestive of acute kidney injury. 43 Isavuconazole, has many advantages compared to other azoles, as it has linear pharmacokinetics, has lesser drug-drug interactions and lesser toxicity. Hepatotoxicity, skin and ocular side-effects, or QT prolongations are not seen; since there is no cyclodextrin in the intravenous formulation, dose adjustment is usually not an issue in patients with renal or hepatic involvement. It also has an excellent oral bioavailability, unlike Posaconazole which has a better absorption in an acidic mileu. 44 An overlap between the first line and the step-down therapy should be done so that therapeutic drug levels are achieved without loss of efficacy of the drug; this is especially true for Posaconazole where therapeutic drug levels need to be monitored. 11.1.6. A summary of the main antifungal agents is provided in Table 5 . 11.1.7. The committee made a conscious note of L-AmB-based intermittent dosing regimen to treat invasive fungal infections but does not recommend its usage outside of a research setting. 45 11.1.8. Other than these two novel azoles, Itraconazole and Terbinafine have also been tested for their efficacy. Besides being sensitive to Posaconazole, Lichtheimia and Syncephalastrum species have shown susceptibility to both Itraconazole and Terbinafine. On the other hand, Cunninghamella species have been reported to be resistant to Posaconazole and Itraconazole but sensitive to Terbinafine. In this era of precision medicine, these findings attest that species identification and AFS should be done, wherever feasible; besides providing a rationalised treatment, the high cost (associated with L-AmB, Isavuconazole and Posaconazole) and drug shortage can also be addressed in resource constrained setups. 32,33,46 11.1.9. Combination therapy of other antifungals, triazoles and echinocandins, with polyenes have not shown to be of advantage. Similarly use of deferasirox, an iron chelator, with L-AmB has also not demonstrated much promise in vivo. The committee recommends against the use of combinations except its usage as a salvage therapy in the hands of an expert. 25 

Being an infective process, that in addition is angioinvasive in nature, thrombolytic therapy is not indicated in patients presenting with stroke. Safety of mechanical thrombectomy also seems doubtful. Decompressive craniectomy may, however, be done in large artery infarcts or space-occupying lesions to reduce intracranial pressure (ICP). 11.4.3. The management of (septic) cerebral venous disease, especially cavernous sinus thrombosis, in patients with C-ROCM is fraught with complications. It has been proposed that thrombosis prevents the spread of infection; therefore, a school of thought advocates against the use of anticoagulants, that otherwise form the mainstay of management in aseptic states. In addition, risk of intracranial as well as systemic haemorrhage remains due to angioinvasive nature of the fungus. There are no trials; certain conclusions, however, can be drawn to aid in its management. 52-54 11.4.3.1. Low molecular weight heparin seems to be better than conventional heparin in terms of tolerance, ease of administration and bleeding complications.

of LMWH may be carried forward with caution in those patients of COVID-19 who had / have deranged coagulation parameters or are at an increased risk. One must be vigilant in patients with meningitis ± cerebritis where an increased risk of haemorrhage is expected. 

There are no randomized studies for the management of ROCM; the recommendations made are essentially based on expert's experience and consensus. 16,23,25 A protocol for surgical interventions has been provided as an algorithm. (Figure 4) Overall, surgical debridement, depending on the site, continues to be an important part in the management of C-ROCM as a part of the standard of care. The scope of surgery may vary from local resection to radical resection of the involved segment/area.

Otorhinolaryngologist's perspective 12.1.1. Endoscopic approach is preferred in patients with early limited disease or those with significant comorbidities. Studies suggest that an open surgery be reserved for an extensive disease, particularly with involvement of CNS or orbits. 25, 55 Surgeries in such cases include maxillectomy, orbital exenteration and or craniofacial resection. Recent data, however, suggests that radical surgeries do not result in any statistically significant improvement in survival, especially in patients with limited life expectancy. Debridement of necrotic tissue in rapidly progressive disease, particularly in diabetics, may increase chances of survival. 56 12.1.2. As a rule of thumb, the extent of debridement is best determined by the ooze of fresh blood from the region of involvement. This concept also holds weight in other regions involved with mucormycosis.

patients is still very high despite of surgical intervention. 57

Oral and Maxillofacial surgeon's perspective 12.2.1. Radical surgical debridement of the diseased tissue harbouring infectious fungal elements, is essential for the successful management of the disease, as it helps to prevent the systemic spread of infection by removal of the nidus. There may sometimes be a need for a repeated debridement based on the disease progression. Local irrigation with AmB or topical hydrogen peroxide helps. Iodoform pack allows secondary granulation and should be changed every 72 hours after irrigation of the wound. 58 The defect should be closed with a custom-made acrylic obturator to prevent local food enlodgement and further infection. 59 

In cases with larger necrotic lesions, signifying an aggressive angio-invasive infection and an advanced spread of disease, more aggressive surgical extirpation may involve radical resection with partial or total maxillectomy or mandibulectomy, as required.

Ophthalmologist's perspective 12.3.1. Orbital involvement in ROCM occurs due to either a direct extension of the disease affecting the paranasal sinuses or through superior orbital fissure or pterygopalatine fossa. Angioinvasion of the Central Retinal artery may lead to Central Retinal artery occlusion (CRAO) while involvement of the cavernous sinus may result in impaired venous flow.

Orbital disease, in the initial stage, consists of unilateral retro-orbital pain (continuous or associated with ocular movements), pre-septal cellulitis, conjunctival chemosis and diplopia. An advanced disease is suggested by the presence of proptosis and total ophthalmoplegia, with or without eyelid discolouration and necrosis. Vision loss accompanies the spread of disease. Sudden onset painless loss of vision, as a result of CRAO, may also occur. A contralateral spread of disease usually indicates cavernous sinus involvement. 3,60 12.3.3. Case specific therapy is guided by the extent of disease. Early disease, with preserved vision, may respond to transcutaneous retrobulbar Amphotericin (TRAMB) injection, 1ml of 3.5mg/ml Amphotericin for 3 days. This may also be given in patients undergoing sinus debridement where the orbital wall is breached. Transient orbital inflammation with amphotericin may be seen in recepients. 61-64 12.3.4. Orbital debridement is indicated for breach of medial wall with medial orbital disease. Disease beyond medial orbit warrants exenteration. 63,64 12.3.5. Vision loss due to CRAO, in the absence of orbital disease, does not warrant any significant orbital debridement and may be dealt with along the sinusinterface.

Neurosurgeon's perspective 12.4.1. Neurosurgical interventions may be needed in case of raised ICP due to hemispheric stroke (decompressive craniectomy), hydrocephalus (CSF diversion procedure), abscess/ granulomas (stereotactic/ ultrasound guided aspiration/ biopsy), helping ENT and Eye surgeons (maximal debridement specifically the contiguously spread fungal elements), and invasive elements in brain parenchyma (maximal safe resection). 24

Reconstructive (Plastic surgery) surgeon's perspective 12.5.1. Breathing pure oxygen under high pressure environment greatly increases the partial pressure of oxygen inhaled. Hyperbaric Oxygen Therapy (HBOT) works on every stage by elevating diffusion rate, diffusion distance, and solubility based on the principles of physics Dalton's law and Henry's law. 65-69 12.5.2. Hyperbaric therapy has been tried in patients with ROCM with cerebral extension as an adjunctive therapy with promising results. 68 The beneficial effects have been attributed to reduction in tissue hypoxia and acidosis that accompany vascular invasion by the fungus. 69 12.5.3. Daily sessions of 45 minutes of HBOT at 1.5 ATM pressure for 2 to 3 weeks is recommended in patients undergoing extensive necrotic tissue debridement.

Anaesthesiologist's perspective 12.6.1. ROC mucormycosis in patients with COVID-19 poses a distinct challenge for anaesthesiologists. Anaesthetic considerations include patient's comorbidities, amphotericin-induced renal and cardiovascular changes, and COVID-19-related multi-organ derangements. As surgical debridement plays a very vital role in the prognosis of ROC mucormycosis, preoperative assessment and optimization is of paramount importance in perioperative management. 70 12.6.2. It is advised that the anaesthesia providers should necessarily review the renal, electrolyte, coagulopathic, hemodynamic, and respiratory abnormalities when the patient in question is receiving amphotericin B therapy. 71 The level of anxiety is these patients is usually high; care must be taken to provide them preoperative anxiolysis. 72 COVID-19 essentially being a respiratory ailment, perioperative ABG analysis is mandatory. 73 12.6.3. Basics of risk stratification (as per American society of Anaesthesiology) and appropriate risk consent, not specifically linked to COVID-19, should be followed. Besides the regular monitoring, invasive monitoring should be done for all patients with hemodynamic compromise. Difficult intubation cart should be ready and necessary precaution should be taken for a potential difficult airway caused by fungal debris and supraglottic oedema in patients with ROC mucormycosis. 74 Use of video laryngoscope is preferable, if available. 12.6.4. Peroperatively, COVID-19 associated deranged lung compliance and pulmonary functions may necessitate close monitoring of plateau and peak pressures. Hypokalaemia due to amphotericin use may enhance effect of skeletal muscle relaxant. Use of amphotericin, especially with concurrent steroid use, provides a perfect milieu for the development of hypokalaemia that may enhance the effect of skeletal muscle relaxant; cardiac arrythmias (all categories) need to be monitored, in addition. Inhalational agents can be used in these patients. 75 12.6.5. Postoperatively, patients with a respiratory rate of >12/minute, tidal volume of >5ml/kg, Spo2 >95% and following verbal commands are the best candidates for extubation before shifting to post-operative care unit. Hemodynamically unstable patients, with no or minimal respiratory effort, should be shifted to post-operative care unit in an intubated condition. Depending on the postoperative status of the patient on the background of comorbidities and the nature of surgery performed, minimal versus extensive, the post-operative care unit may constitute either an ICU or a step-down unit.

Other surgical interventions 12.7.1. Presence of a pulmonary cavitary lesion (fungal ball) or extensive involvement of the lung, secondary to Mucormycosis, may necessitate resection of the lesion or lobectomy (with or without pneumonectomy) to improve the outcome. 76 Overall, the prognosis of such patients is worse than that seen with pulmonary aspergillosis. 76-78 12.7.2. It may be highlighted that dual-pathology (pulmonary aspergillosis in patients with C-ROCM) has been noted in at least 4 of our evaluated patients; thus, all lesions in the lung may not be related to Mucormycosis alone. A recent report has also noted dual-pathology, within the same site. 79 Thus, all efforts ranging from serology for aspergillus to tissue diagnosis must be made to address the diagnostic dilemma. The medical management of pulmonary aspergillosis may be done as per recommendations. 78 13. COVID-19 associated Mucormycosis may be summarized as: 13.1. ROCM is a rapidly progressive disease with an average mortality of around 40%. 13.2.

The unprecedented rise in cases of C-ROCM may be related to either agentrelated or host-related factors. 13.3.

Diabetes, historically, and inadvertent use of corticosteroids, in the current scenario, appear to be the commonest predisposing factors for the development of C-ROCM. 13.4 .

Prevention of C-ROCM essentially revolves around judicious use of corticosteroids and managing hyperglycaemia effectively. 13.5.

A high index of suspicion should be there to diagnose C-ROCM. 13.6.

Diagnostic nasal endoscopy forms the first step in diagnosing C-ROCM. Prompt transport of the specimen obtained helps in initiating an early treatment. 13.7.

All specimen should be subject to species identification and AFST, if available. 13.8. A revised staging system is proposed to aid in site-and-side specific categorisation along with the extent of the disease. 13.9.

The primary drug of choice in managing patients with C-ROCM is Amphotericin B, preferably liposomal, followed by isavuconazole and posaconazole. More data on itraconazole and terbinafine is required to recommend its usage. 13.10.

Management of mucormycosis is incomplete without an effective debridement strategy depending on the region involved. 13.11.

Follow up surgeries directed towards rehabilitation and reconstruction should be undertaken to improve long-term outcome. 

Summary of preventive aspects of C-ROCM Good general practices:

 No tubes (hydration, nebulization, ventilation), masks (Hudson, NRM, NIV) or prongs to be reused.  Common use equipment viz. nebulizers, BiPaP machines and Ventilatory units, must follow a standard decontamination process when changeover is done.

 It is advised that only distilled water is used for the purpose of hydration.  If distilled water is not available, it should be ensured that water used for hydration of oxygen delivery, steam inhalation or ventilation delivery unit is clean; refilling should be done only after clearing and cleaning of the residua in the jar.

 Prevention of use of contaminated linen.  Regulations required to prevent contamination of patient-care areas (not alone ICUs or HDUs) by dust, dampness, water leakage, etc.

 Monitoring of passages (leading to patient-care areas) and AHU.  Monitored use of antibiotics (broad-spectrum vs based on antibiogram) and antifungals (based on species identification and anti-fungal susceptibility testing)  Use of masks by the patients even in the treatment units, especially those with negative pressure. Appropriate glycaemic control with regular monitoring to prevent hyperglycaemia and ketosis Judicious use of steroids  No steroids to be given to those with SpO2 is >94% or those who do NOT require supplemental oxygen (CDC Protocol)

 Singular use, especially in the first 5-7 days, without an anti-viral cover is strongly discouraged.  Dexamethasone: 6mg/day for not more than 10 days (WHO Protocol)  High dose steroids use should be reserved for specialists or those trained in handling these patients Weekly nasal endoscopy by the Otorhinolaryngologist of all earmarked as high-risk for C-ROCM J o u r n a l P r e -p r o o f 

A meta-analysis of survival factors in rhinoorbital-cerebral mucormycosis-has anything changed in the past 20 years?

Epidemiology and Diagnosis of Mucormycosis: An Update. J Fungi (Basel)

Epidemiology of Mucormycosis in India. Microorganisms

Ten years' experience in zygomycosis at a tertiary care centre in India

The rising trend of invasive zygomycosis in patients with uncontrolled diabetes mellitus

Invasive zygomycosis in India: experience in a tertiary care hospital

Epidemiology and outcome of zygomycosis: a review of 929 reported cases

Spectrum of zygomycete species identified in clinically significant specimens in the United States

The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports

Host-Pathogen Molecular Factors Contribute to the Pathogenesis of Rhizopus spp

Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage

Pathogenesis of mucormycosis

Expression Patterns in Reductive Iron Assimilation and Functional Consequences during Phagocytosis of Lichtheimia corymbifera, an Emerging Cause of Mucormycosis. J Fungi (Basel)

Semin Respir Crit Care Med

Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19

Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks

Fungal contamination of nebuliser devices used by people with cystic fibrosis

What was known and what is really new? Diabetes Res Clin Pract

When Uncontrolled Diabetes Mellitus and Severe COVID-19 Converge: The Perfect Storm for Mucormycosis. J Fungi (Basel)

Hyperglycemia in Acute COVID-19 is Characterized by Adipose Tissue Dysfunction and Insulin Resistance. medRxiv

The trinity of COVID-19: immunity, inflammation and intervention

Current therapeutic protocols for chronic granulomatous fungal sinusitis

Mucormycosis of the Central Nervous System

Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium

Sinonasal Mucormycosis: A to Z

Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis)

Principles and Procedures for Detection and culture of Fungi in Clinical Specimens

Laboratory diagnosis of mucormycosis: current status and future perspectives

A prospective study of mucormycosis in north India: experience from a tertiary care hospital

Identification of Molds by Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry

Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous fungi: Approved Standard-Second Edition. CLSI Document M 38-A2

Antifungal resistance in mucorales

Rhino-orbito-cerebral mucormycosis: Magnetic resonance imaging

Periantral soft-tissue infiltration and its relevance to the early detection of invasive fungal sinusitis: CT and MR findings

Perineural spread of rhino-orbitocerebral mucormycosis caused by Apophysomyces elegans

Diffusion-weighted imaging of fungal cerebral infection

Black Turbinate" sign: An early MR imaging finding of nasal mucormycosis

Guitar pick sign" on MRI

The pterygopalatine fossa: imaging anatomy, communications, and pathology revisited. Insights Imaging

Amphotericin B formulations: a comparative review of efficacy and toxicity

The RIFLE criteria and mortality in acute kidney injury: A systematic review

Recent advances in the treatment of mucormycosis. Curr Infect Dis Rep

Outpatient parenteral antifungal therapy (OPAT) for invasive fungal infections with intermittent dosing of liposomal amphotericin B. Med Mycol

Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species

Challenges in the diagnosis and treatment of mucormycosis

Contemporary management and clinical outcomes of mucormycosis: A systematic review and metaanalysis of case reports

Diabetes mellitus as the major risk factor for mucormycosis in Mexico: Epidemiology, diagnosis, and outcomes of reported cases

Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis

Environmental interactions with amoebae as drivers of bacterial-fungal endosymbiosis and pathogenicity. bioRxiv

Septic cerebral venous sinus thrombosis

Diagnosis and Management of Cerebral Venous Diseases in Neuro-Ophthalmology: Ongoing Controversies

Septic cavernous sinus thrombosis: A review

Acute invasive fungal rhinosinusitis: evaluation of 26 patients treated with endonasal or open surgical procedures. Otolaryngol Head Neck Surg

Treatment outcomes in acute invasive fungal rhinosinusitis

Invasive mould sinusitis in patients with haematological malignancies: a 10 year single-centre study

Iodoform gauze removes necrotic tissue from pressure ulcer wounds by fibrinolytic activity

Rhinocerebral Mucormycosis: A Prospective Analysis of an Effective Treatment Protocol. Ann Maxillofac Surg

COVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19

Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis

Invasive fungal sinusitis: treatment of the orbit

Outcomes of a Modified Treatment Ladder Algorithm using Retrobulbar Amphotericin B for Invasive Fungal Rhino-Orbital Sinusitis

Transcutaneous retrobulbar amphotericin B and exenteration in rhino-orbital cerebral mucor mycosis: Do we know it all yet?

Hyperbaric oxygen as an adjunctive treatment for zygomycosis

Hyperbaric oxygen therapy may be effective to improve hypoxemia in patients with severe COVID-2019 pneumonia: two case reports

Hyperbaric oxygen therapy: Can it be a novel supportive therapy in COVID-19?

Rhinocerebral mucormycosis with cerebral extension successfully treated with adjunctive hyperbaric oxygen therapy

Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis

Post-traumatic invasive mucormycosis

Anesthetic management for lobectomy in a patient with coccidioidomycosis: a case report

Cerebro-rhino orbital mucormycosis: an update

Anesthetic considerations in the management of mucormycosis

Anesthetic management of rhinoorbitocerebral mucormycosis; Focus on challenges

Antimicrobial effects of liquid anesthetic isoflurane on Candida albicans

Pulmonary mucormycosis. Semin Respir Crit Care Med

Advances in the diagnosis and management of pulmonary aspergillosis

European Confederation of Medical Mycology

Infectious Diseases Fungal Infection Study Group; ESCMID Study Group for Infections in Critically Ill Patients; Interregional Association of Clinical Microbiology and Antimicrobial Chemotherapy; Medical Mycology Society of Nigeria; Medical Mycology Society of China Medicine Education Association; Infectious Diseases Working Party of the German Society for Haematology and Medical Oncology

Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance

Pulmonary aspergillosis and mucormycosis in a patient with COVID-19

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.The following questions apply to the author's relationships/activities/interests as they relate to the current manuscript only.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

Specifications/Comments (e.g., if payments were made to you or to your institution) Time frame: Since the initial planning of the work 1All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.) No time limit for this item. Please place an "X" next to the following statement to indicate your agreement:

___ I certify that I have answered every question and have not altered the wording of any of the questions on this form. X